Enabling Clinical Trials and Translational Studies with Twist

Shubha Anand | University of Cambridge

alt text
Presented by
Shubha Anand
Shubha Anand
University of Cambridge
Ezequiel Martin
Ezequiel Martin
University of Cambridge

Covered in this Webinar
How the CMD Lab are using three capture-based panels from TWIST Bioscience for molecular analysis in 3 trials
A 350-gene pan-cancer panel to perform sequencing of matched germline & tumor samples (FFPE) for the BoB trial
A 56-gene myeloid panel to investigate an association between Clonal Haematopoiesis & Severe COVID-19 disease
A 150-gene lymphoma panel that is being tested on ctDNA for a Diffuse Large B cell lymphoma (DLBCL) trial

The Cancer Molecular Diagnostics Laboratory is based in University of Cambridge, Department of Oncology and is funded by NIHR Cambridge Biomedical Research Centre, The Mark Foundation for Cancer Research & The Cancer Research UK Cambridge Centre. The laboratory supports translational research studies and clinical trials taking place in the Cambridge Biomedical Campus. In this talk we will be showing how we are using three capture-based panels from TWIST Bioscience for molecular analysis in three different trials. We are utilizing a 350-gene pan-cancer panel to perform sequencing of matched germline and tumour samples (FFPE) for the Basket of Baskets (BoB) trial of Cancer Core Europe (CCE). In addition, we have a 56-gene myeloid panel designed by Prof. G Vassiliou at the Dept. of Haematology, University of Cambridge, who is investigating an association between Clonal Haematopoiesis and Severe COVID-19 disease. Lastly, we are also testing a 150-gene lymphoma panel on ctDNA for a Diffuse Large B cell lymphoma (DLBCL) trial (Lead PI: Dr Dan Hodson, Dept. of Haematology, University of Cambridge) to establish a platform for precision medicine in DLBCL.

Share your details to Watch the Webinar